Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study.
The current drug treatment for Alzheimer's disease (AD) is only partially and temporary effective. Transcranial magnetic stimulation (TMS) is a non-invasive technique that generates an electric current inducing modulation in cortical excitability. In addition, cognitive training (COG) may improve cognitive functions in AD. Our aim was to treat AD patients combining high-frequency repetitive TMS interlaced with COG (rTMS-COG). Eight patients with probable AD, treated for more than 2 months with cholinesterase inhibitors, were subjected to daily rTMS-COG sessions (5/week) for 6 weeks, followed by maintenance sessions (2/week) for an additional 3 months. Six brain regions, located individually by MRI, were stimulated. COG tasks were developed to fit these regions. Primary objectives were average improvement of Alzheimer Disease Assessment Scale-Cognitive (ADAS-cog) and Clinical Global Impression of Change (CGIC) (after 6 weeks and 4.5 months, compared to baseline). Secondary objectives were average improvement of MMSE, ADAS-ADL, Hamilton Depression Scale (HAMILTON) and Neuropsychiatric Inventory (NPI). One patient abandoned the study after 2 months (severe urinary sepsis). ADAS-cog (average) improved by approximately 4 points after both 6 weeks and 4.5 months of treatment (P < 0.01 and P < 0.05) and CGIC by 1.0 and 1.6 points, respectively. MMSE, ADAS-ADL and HAMILTON improved, but without statistical significance. NPI did not change. No side effects were recorded. In this study, rTMS-COG (provided by Neuronix Ltd., Yokneam, Israel) seems a promising effective and safe modality for AD treatment, possibly as good as cholinesterase inhibitors. A European double blind study is underway.
Neuronix Ltd, Yokneam, Israel.
Jonathan
J
Bentwich
Evgenia
E
Dobronevsky
Sergio
S
Aichenbaum
Ran
R
Shorer
Ruth
R
Peretz
Michael
M
Khaigrekht
Revital Gandelman
RG
Marton
Jose M
JM
Rabey
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003071:Cognition; D005260:Female; D005702:Galantamine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011214:Practice, Psychological; D011569:Psychiatric Status Rating Scales; D050781:Transcranial Magnetic Stimulation; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D005702:Galantamine
Int J Geriatr Psychiatry. 2009 May;24(5):532-8
19274640
Biol Psychiatry. 1999 Dec 15;46(12):1603-13
10624541
Cortex. 2009 Oct;45(9):1097-103
19251255
Br J Psychiatry. 2005 Nov;187:450-5
16260821
Neurology. 2000;54(11 Suppl 5):S10-5
10854355
J Neurosci Methods. 2008 Jul 30;172(2):270-6
18533272
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Cogn Neuropsychol. 2008 Jun;25(4):528-58
19086201
Brain. 2006 Jul;129(Pt 7):1659-73
16672292
Drugs. 2006;66(11):1515-34
16906789
J Clin Psychiatry. 1980 Dec;41(12 Pt 2):21-4
7440521
Neuroreport. 1994 May 9;5(9):1157-60
8080978
Dementia. 1996 Nov-Dec;7(6):293-303
8915035
Neurology. 2001 Feb 27;56(4):526-8
11222799
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191
19370562
Int J Geriatr Psychiatry. 2005 May;20(5):446-51
15852436
Nature. 1993 Jan 7;361(6407):31-9
8421494
Brain. 1997 Jul;120 ( Pt 7):1229-44
9236633
Exp Brain Res. 2003 Jan;148(1):1-16
12478392
J Magn Reson Imaging. 2000 Jun;11(6):569-74
10862054
Acta Psychiatr Scand. 2006 Aug;114(2):75-90
16836595
Alzheimers Dement. 2007 Jul;3(3):186-91
19595937
J Neural Transm (Vienna). 2010 Jan;117(1):105-22
19859782
Biol Psychiatry. 1999 Feb 15;45(4):385-94
10071706
Biol Psychiatry. 1999 Mar 15;45(6):759-63
10188006
Arch Neurol. 2003 Aug;60(8):1119-22
12925369
Neuropsychologia. 2001;39(13):1419-31
11585610
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593
16437532
Int J Neuropsychopharmacol. 2000 Sep;3(3):259-273
11343603
Exp Brain Res. 2007 Jul;180(4):583-93
17562028
Clin Neurophysiol. 2009 Dec;120(12):2008-2039
19833552
Neuroepidemiology. 2007;29(1-2):125-32
17975326
Annu Rev Public Health. 1989;10:115-40
2655627
Learn Mem. 2009 Jun 24;16(7):433-8
19553381
Brain. 2008 Oct;131(Pt 10):2742-50
18757465
J Cogn Neurosci. 2004 Mar;16(2):289-300
15068598
J Neuropathol Exp Neurol. 2000 Apr;59(4):308-13
10759186
Am J Psychiatry. 1984 Nov;141(11):1356-64
6496779
Neurology. 1994 Dec;44(12):2308-14
7991117
Front Hum Neurosci. 2008 Oct 06;2:14
18958214
J Int Neuropsychol Soc. 2002 Mar;8(3):448-60
11939702
J ECT. 1998 Sep;14(3):194-205
9773358
Neuropsychologia. 2009 Jan;47(2):295-302
18822306
Arch Neurol. 2006 Nov;63(11):1602-4
17101829
Electroencephalogr Clin Neurophysiol. 1996 Oct;101(5):412-7
8913194
Arch Gen Psychiatry. 2010 May;67(5):507-16
20439832
Br J Psychiatry. 2003 Sep;183:248-54
12948999
J Neurol Neurosurg Psychiatry. 2006 Oct;77(10):1116-21
16820420
Lancet. 1977 Jan 22;1(8004):189
64712
Neuroimage. 2002 Apr;15(4):936-48
11906234
Prog Brain Res. 1990;84:321-32
2267306
Neurosci Lett. 2005 Sep 2;385(1):18-23
15970381
Psychiatry Res. 2000 Dec 4;100(2):75-80
11114493
J Physiol. 1997 Feb 1;498 ( Pt 3):817-23
9051592
J Neurol Neurosurg Psychiatry. 1996 May;60(5):478-88
8778250